(Q37820674)

23 August 2017

1 reference

title

Pharmacoeconomics of voriconazole in the management of invasive fungal infections (English)

1 reference

invasive fungal infections

23 August 2017

1 reference

1 reference

3

0 references

Monica Slavin

4

0 references

author name string

Daoud Al-Badriyeh

1

1 reference

23 August 2017

Siow Chin Heng

2

1 reference

23 August 2017

Kay Stewart

5

1 reference

23 August 2017

David C M Kong

6

1 reference

23 August 2017

publication date

1 December 2010

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

623-636

1 reference

Invasive fungal infections: past achievements and challenges ahead.

23 August 2017

cites work

1 reference

Changing epidemiology of systemic fungal infections.

21 January 2018

1 reference

Phaeohyphomycosis in a tertiary care cancer center

21 January 2018

1 reference

Fungal infections after bone marrow transplant

21 January 2018

1 reference

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients

21 January 2018

1 reference

Oral antifungals as prophylaxis in haematological malignancy

21 January 2018

1 reference

Prophylaxis and treatment of fungal infections associated with haematological malignancies

21 January 2018

1 reference

Fungal infections in cancer patients: an international autopsy survey.

21 January 2018

1 reference

Human mycoses: drugs and targets for emerging pathogens

21 January 2018

1 reference

Burden of hospitalization of patients with Candida and Aspergillus infections in Australia

21 January 2018

1 reference

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

Fungal cell wall inhibitors: emphasis on clinical aspects

21 January 2018

1 reference

Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations

21 January 2018

1 reference

Posaconazole: a broad-spectrum triazole antifungal

21 January 2018

1 reference

Mechanism of fluid transport across corneal endothelium and other epithelial layers: a possible explanation based on cyclic cell volume regulatory changes

21 January 2018

1 reference

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent

21 January 2018

1 reference

Use of voriconazole in the treatment of fungal keratitis.

21 January 2018

1 reference

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients

21 January 2018

1 reference

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients

21 January 2018

1 reference

Clinical pharmacokinetics of voriconazole.

21 January 2018

1 reference

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

Voriconazole pharmacokinetics and pharmacodynamics in children

21 January 2018

1 reference

Antifungal therapeutic drug monitoring: established and emerging indications

21 January 2018

1 reference

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies

21 January 2018

1 reference

Torsades de pointes associated with voriconazole use.

21 January 2018

1 reference

Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole

21 January 2018

1 reference

Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients

21 January 2018

1 reference

Empiric antifungal therapy in neutropenic cancer patients

21 January 2018

1 reference

Strategies for managing systemic fungal infection and the place of itraconazole

21 January 2018

1 reference

Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.

21 January 2018

1 reference

Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis

21 January 2018

1 reference

Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium

21 January 2018

1 reference

Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.

21 January 2018

1 reference

Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands

21 January 2018

1 reference

Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis

21 January 2018

1 reference

Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.

21 January 2018

1 reference

Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients

21 January 2018

1 reference

Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study

21 January 2018

1 reference

Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia

21 January 2018

1 reference

Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia

21 January 2018

1 reference

Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.

21 January 2018

1 reference

Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.

21 January 2018

1 reference

Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia

21 January 2018

1 reference

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients

21 January 2018

1 reference

Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results

21 January 2018

1 reference

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

21 January 2018

1 reference

Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis

21 January 2018

1 reference

Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.

21 January 2018

1 reference

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

The U.K. NHS economic evaluation database. Economic issues in evaluations of health technology

21 January 2018

1 reference

Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever

21 January 2018

1 reference

Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.

21 January 2018

1 reference

Azole-resistant central nervous system aspergillosis.

21 January 2018

1 reference

Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis

21 January 2018

1 reference

27 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1111/J.1399-3062.2007.00210.X

Identifiers

DOI

10.1586/ERP.10.69

1 reference

23 August 2017

1 reference